Association Between Clozapine Plasma Concentrations and Treatment Response: A Systematic Review, Meta-analysis and Individual Participant Data Meta-analysis.
Journal
Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
accepted:
26
03
2023
medline:
12
6
2023
pubmed:
5
5
2023
entrez:
5
5
2023
Statut:
ppublish
Résumé
Although therapeutic drug monitoring of clozapine is recommended, its optimisation is often adjusted only on the basis of dosage. The aim of this study was to assess the link between clozapine plasma concentrations and clinical response by a meta-analysis of published studies and by an individual participant data meta-analysis. We conducted a computerised search of bibliographic databases (EMBASE, PubMed, Clinical Trials, and Web of Science) to identify studies that assessed the relationship between clozapine serum or plasma concentrations and clinical efficacy. Using pooled data, we investigated the association between improvement of clinical outcome and clozapine or norclozapine plasma concentrations, the sum of clozapine and norclozapine plasma concentrations, and the coefficient of variation of clozapine plasma concentrations. Using available individual data, we assessed the relationship between clozapine plasma concentrations and clinical response (changes in the Brief Psychiatric Rating Scale score) and identified a threshold level for a favourable clinical response. Fifteen studies satisfied inclusion criteria. Our meta-analysis showed that responders had clozapine plasma concentrations that were, on average, 117 ng/mL higher than non-responders. The patients with plasma clozapine concentrations above the thresholds identified in each study had a higher likelihood of responding (odds ratio = 2.94, p < 0.001). Norclozapine plasma concentrations were not associated with a clinical response. The meta-analysis of individual data supported this result and confirmed the link between clozapine concentrations and a change in the Brief Psychiatric Rating Scale score and/or the probability of clinical response. Finally, with the analysis of the coefficient of variation of clozapine plasma concentrations, we found that a greater inter-individual fluctuation in plasma concentrations was associated with a loss of clinical response. Our work confirmed that, in contrast to clozapine doses, clozapine plasma concentrations were related to a favourable clinical response, with a mean difference between responders and non-responders of 117 ng/mL. A threshold for a treatment response of 407 ng/mL was determined, with a high discriminatory capacity, and a sensitivity and specificity of 71% and 89.1%, respectively.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Although therapeutic drug monitoring of clozapine is recommended, its optimisation is often adjusted only on the basis of dosage. The aim of this study was to assess the link between clozapine plasma concentrations and clinical response by a meta-analysis of published studies and by an individual participant data meta-analysis.
METHODS
METHODS
We conducted a computerised search of bibliographic databases (EMBASE, PubMed, Clinical Trials, and Web of Science) to identify studies that assessed the relationship between clozapine serum or plasma concentrations and clinical efficacy. Using pooled data, we investigated the association between improvement of clinical outcome and clozapine or norclozapine plasma concentrations, the sum of clozapine and norclozapine plasma concentrations, and the coefficient of variation of clozapine plasma concentrations. Using available individual data, we assessed the relationship between clozapine plasma concentrations and clinical response (changes in the Brief Psychiatric Rating Scale score) and identified a threshold level for a favourable clinical response.
RESULTS
RESULTS
Fifteen studies satisfied inclusion criteria. Our meta-analysis showed that responders had clozapine plasma concentrations that were, on average, 117 ng/mL higher than non-responders. The patients with plasma clozapine concentrations above the thresholds identified in each study had a higher likelihood of responding (odds ratio = 2.94, p < 0.001). Norclozapine plasma concentrations were not associated with a clinical response. The meta-analysis of individual data supported this result and confirmed the link between clozapine concentrations and a change in the Brief Psychiatric Rating Scale score and/or the probability of clinical response. Finally, with the analysis of the coefficient of variation of clozapine plasma concentrations, we found that a greater inter-individual fluctuation in plasma concentrations was associated with a loss of clinical response.
CONCLUSIONS
CONCLUSIONS
Our work confirmed that, in contrast to clozapine doses, clozapine plasma concentrations were related to a favourable clinical response, with a mean difference between responders and non-responders of 117 ng/mL. A threshold for a treatment response of 407 ng/mL was determined, with a high discriminatory capacity, and a sensitivity and specificity of 71% and 89.1%, respectively.
Identifiants
pubmed: 37145296
doi: 10.1007/s40262-023-01247-1
pii: 10.1007/s40262-023-01247-1
doi:
Substances chimiques
Clozapine
J60AR2IKIC
Antipsychotic Agents
0
Types de publication
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
807-818Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
World Health Organization (WHO), editor. Schizophrenia. WHO, 10 January 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/schizophrenia . Accessed 21 Apr 2023.
Chong HY, Teoh SL, Wu DB-C, Kotirum S, Chiou C-F, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357–73.
pubmed: 26937191
pmcid: 4762470
Kim D. Indicators of response to clozapine treatment. Mental Health Clin. 2015;5:74–7.
doi: 10.9740/mhc.2015.03.074
Nucifora FC, Woznica E, Lee BJ, Cascella N, Sawa A. Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2019;131: 104257.
pubmed: 30170114
doi: 10.1016/j.nbd.2018.08.016
Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789–96.
pubmed: 3046553
doi: 10.1001/archpsyc.1988.01800330013001
Correll CU, Howes OD. Treatment-resistant schizophrenia: definition, predictors, and therapy options. J Clin Psychiatry. 2021;82.
Kerwin R. When should clozapine be initiated in schizophrenia? CNS Drugs. 2007;21:267–78.
pubmed: 17381182
doi: 10.2165/00023210-200721040-00002
Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001;158:518–26.
pubmed: 11282684
doi: 10.1176/appi.ajp.158.4.518
Lewis SW, Barnes TRE, Davies L, Murray RM, Dunn G, Hayhurst KP, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006;32:715–23.
pubmed: 16540702
pmcid: 2632262
doi: 10.1093/schbul/sbj067
McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163:600–10.
pubmed: 16585434
doi: 10.1176/ajp.2006.163.4.600
Schatzberg AF, DeBattista C. Manual of clinical psychopharmacology, 8th edn. Arlington, VA, US: American Psychiatric Publishing, Inc.; 2015. p. xxiii, 117.
Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry. 2007;18:39–60.
pubmed: 17580753
doi: 10.1177/0957154X07070335
Wenthur CJ, Lindsley CW. Classics in chemical neuroscience: clozapine. ACS Chem Neurosci. 2013;4:1018–25.
pubmed: 24047509
pmcid: 3715841
doi: 10.1021/cn400121z
Honigfield G. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Psychiatr Serv. 1996;47:52–6.
doi: 10.1176/ps.47.1.52
Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry. 2014;14:102.
pubmed: 24708834
pmcid: 3999500
doi: 10.1186/1471-244X-14-102
Chakrabarti S. Clozapine resistant schizophrenia: newer avenues of management. World J Psychiatry. 2021;11:429–48.
pubmed: 34513606
pmcid: 8394694
doi: 10.5498/wjp.v11.i8.429
Aissa A, Jouini R, Ouali U, Zgueb Y, Nacef F, El Hechmi Z. Clinical predictors of response to clozapine in Tunisian patients with treatment resistant schizophrenia. Compr Psychiatry. 2022;112: 152280.
pubmed: 34763293
doi: 10.1016/j.comppsych.2021.152280
Bersani FS, Capra E, Minichino A, Pannese R, Girardi N, Marini I, et al. Factors affecting interindividual differences in clozapine response: a review and case report. Hum Psychopharmacol. 2011;26:177–87.
pubmed: 21455971
Lane HY, Chang YC, Chang WH, Lin SK, Tseng YT, Jann MW. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry. 1999;60:36–40.
pubmed: 10074876
doi: 10.4088/JCP.v60n0108
de Leon J, Ruan C-J, Schoretsanitis G, De las Cuevas C. A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology. Psychother Psychosom. 2020;89:200–14.
pubmed: 32289791
doi: 10.1159/000507638
Ruan C-J, Zang Y-N, Cheng Y-H, Wang C-Y, de Leon J. Around 3% of 1,300 levels were elevated during infections in a retrospective review of 131 Beijing hospital in-patients with more than 24,000 days of clozapine treatment. Psychother Psychosom. 2020;89:255–7.
pubmed: 32114581
doi: 10.1159/000506355
Jerling M, Lindström L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit. 1994;16:368–74.
pubmed: 7974626
doi: 10.1097/00007691-199408000-00006
Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007;100:4–22.
pubmed: 17214606
doi: 10.1111/j.1742-7843.2007.00017.x
Hägg S, Spigset O, Mjörndal T, Dahlqvist R. Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2000;49:59–63.
pubmed: 10606838
pmcid: 2014893
doi: 10.1046/j.1365-2125.2000.00111.x
Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol. 1993;13:383–90.
pubmed: 8120151
doi: 10.1097/00004714-199312000-00003
Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P, Eap CB. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit. 2005;27:539–43.
pubmed: 16044115
doi: 10.1097/01.ftd.0000164609.14808.93
Facciolà G, Avenoso A, Spina E, Perucca E. Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia. Ther Drug Monit. 1998;20:628–30.
pubmed: 9853978
doi: 10.1097/00007691-199812000-00008
Djerada Z, Daviet F, Llorca P-M, Eschalier A, Saint-Marcoux F, Bentué-Ferrer D, et al. Suivi thérapeutique pharmacologique de la clozapine. Thérapie [Internet]. 2016 [cited 2023 Apr 24]. https://www.sciencedirect.com/science/article/pii/S0040595716311325 .
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–12.
pubmed: 10789670
doi: 10.1001/jama.283.15.2008
Eriksen MB, Frandsen TF. The impact of Patient, Intervention, Comparison, Outcome (PICO) as a search strategy tool on literature search quality: a systematic review. J Med Libr Assoc. 2018;106:420–31.
pubmed: 30271283
pmcid: 6148624
doi: 10.5195/jmla.2018.345
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009;3:e123–30.
pubmed: 21603045
pmcid: 3090117
Wong JO-Y, Leung S, Mak T, Ng RM, Chan K, Hon-Kee Cheung H, et al. Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:251–64.
pubmed: 16316716
doi: 10.1016/j.pnpbp.2005.10.008
Dettling M, Sachse C, Brockmöller J, Schley J, Müller-Oerlinghausen B, Pickersgill I, et al. Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. Psychopharmacology. 2000;152:80–6.
pubmed: 11041319
doi: 10.1007/s002130000503
Hussein R, Gad A, Raines DA, Chaleby K, Al-Rawithi S, El-Yazigi A. Steady-state pharmacokinetics of clozapine in refractory schizophrenic Saudi Arabian patients. Pharm Pharmacol Commun. 1999;5:473–8.
doi: 10.1211/146080899128735108
Chong S-A, Tan C-H, Khoo Y-M, Lee H-S, Wong K-E, Ngui F, et al. Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia. Ther Drug Monit. 1997;19:219–23.
pubmed: 9108654
doi: 10.1097/00007691-199704000-00018
Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S, Jin Y, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry. 1994;55 Suppl B:133–6.
pubmed: 7961557
Spina E, Avenoso A, Facciolà G, Scordo MG, Ancione M, Madia AG, et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology. 2000;148:83–9.
pubmed: 10663421
doi: 10.1007/s002130050028
Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry. 1991;148:231–5.
pubmed: 1670979
Siskind D, Sharma M, Pawar M, Pearson E, Wagner E, Warren N, Kisely S. Clozapine levels as a predictor for therapeutic response: a systematic review and meta-analysis. Acta Psychiatr Scand. 2021;144(5):422–32.
pubmed: 34374073
doi: 10.1111/acps.13361
Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799–812.
doi: 10.2466/pr0.1962.10.3.799
Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1–48.
doi: 10.18637/jss.v036.i03
Nakagawa S, Poulin R, Mengersen K, Reinhold K, Engqvist L, Lagisz M, et al. Meta-analysis of variation: ecological and evolutionary applications and beyond. Method Ecol Evol. 2015;6:143–52.
doi: 10.1111/2041-210X.12309
Stewart GB, Altman DG, Askie LM, Duley L, Simmonds MC, Stewart LA. Statistical analysis of individual participant data meta-analyses: a comparison of methods and recommendations for practice. PLoS ONE. 2012;7: e46042.
pubmed: 23056232
pmcid: 3463584
doi: 10.1371/journal.pone.0046042
Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010;340: c221.
pubmed: 20139215
doi: 10.1136/bmj.c221
Zheng Y-P, Lin K-M, Zhao J-P, Zhang M-Y, Yong D. Comparative study of diagnostic systems: Chinese classification of Mental Disorders-Second Edition versus DSM-III-R. Compr Psychiatry. 1994;35:441–9.
pubmed: 7867317
doi: 10.1016/0010-440X(94)90227-5
Yuanguang C, Zhao J, Xie G. A study on serum concentration and clinical response to clozapine with different dose administration for treatment of schizophrenia. Chinese J Psychiatry. 1998;31(2):104–7.
VanderZwaag C, McGee M, McEvoy JP, Freudenreich O, Wilson WH, Cooper TB. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry. 1996;153:1579–84.
pubmed: 8942454
doi: 10.1176/ajp.153.12.1579
Kaladjian A, Bery B, Deturmeny E, Bruguerolle B. Clozapine monitoring: plasma or serum levels? Ther Drug Monit. 1999;21:327–9.
pubmed: 10365647
doi: 10.1097/00007691-199906000-00014
Hermida J, Paz E, Tutor JC. Clozapine and norclozapine concentrations in serum and plasma samples from schizophrenic patients. Ther Drug Monit. 2008;30:41–5.
pubmed: 18223461
doi: 10.1097/FTD.0b013e31815f4e72
Kronig MH, Munne RA, Szymanski S, Safferman AZ, Pollack S, Cooper T, et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry. 1995;152:179–82.
pubmed: 7840349
doi: 10.1176/ajp.152.2.179
Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9–62.
pubmed: 28910830
doi: 10.1055/s-0043-116492
Schoretsanitis G, Kane JM, Correll CU, Marder SR, Citrome L, Newcomer JW, et al. Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry. 2020;81:3649.
doi: 10.4088/JCP.19cs13169
Llorca P-M, Lancon C, Disdier B, Farisse J, Sapin C, Auquier P. Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations. J Psychiatry Neurosci. 2002;27:30–7.
pubmed: 11836974
pmcid: 149793
Miller DD, Fleming F, Holman TL, Perry PJ. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry. 1994;55 Suppl B:117–21.
pubmed: 7961554
Fabrazzo M, La Pia S, Monteleone P, Esposito G, Pinto A, De Simone L, et al. Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. Neuropsychopharmacology. 2002;27:1050–5.
pubmed: 12464462
doi: 10.1016/S0893-133X(02)00319-6
Yada Y, Kitagawa K, Sakamoto S, Ozawa A, Nakada A, Kashiwagi H, et al. The relationship between plasma clozapine concentration and clinical outcome: a cross-sectional study. Acta Psychiatr Scand. 2021;143:227–37.
pubmed: 33274435
doi: 10.1111/acps.13264
Mauri M, Volonteri LS, Fiorentini A, Invernizzi G, Nerini T, Baldi M, et al. Clinical outcome and plasma levels of clozapine and norclozapine in drug-resistant schizophrenic patients. Schizophr Res. 2004;66:197–8.
pubmed: 15061256
doi: 10.1016/S0920-9964(03)00159-2
PHD AK MD. Clozapine fixed dose steady state plasma levels and the relationship to the polymorphism of CYP1A2, CYP3A4, CYP3A5 and CYP2D6 in clinically stable schizophrenic adult patients. 2017 Oct. Report No.: NCT01663077. Available from: https://clinicaltrials.gov/ct2/show/NCT01663077 . Accessed 21 Apr 2023.
Gaertner I, Gaertner HJ, Vonthein R, Dietz K. Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. J Clin Psychopharmacol. 2001;21:305–10.
pubmed: 11386494
doi: 10.1097/00004714-200106000-00010
Stieffenhofer V, Saglam H, Schmidtmann I, Silver H, Hiemke C, Konrad A. Clozapine plasma level monitoring for prediction of rehospitalization schizophrenic outpatients. Pharmacopsychiatry. 2011;44:55–9.
pubmed: 21207352
doi: 10.1055/s-0030-1267178
Konecki C, Feliu C, Cazaubon Y, Giusti D, Tonye-Libyh M, Brixi H, et al. External evaluation of population pharmacokinetic models and Bayes-based dosing of infliximab. Pharmaceutics. 2021;13:1191.
pubmed: 34452152
pmcid: 8398005
doi: 10.3390/pharmaceutics13081191
Cazaubon Y, Talineau Y, Feliu C, Konecki C, Russello J, Mathieu O, et al. Population pharmacokinetics modelling and simulation of mitotane in patients with adrenocortical carcinoma: an individualized dose regimen to target all patients at three months? Pharmaceutics. 2019;11:E566.
doi: 10.3390/pharmaceutics11110566
Jerling M, Merlé Y, Mentré F, Mallet A. Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. Br J Clin Pharmacol. 1997;44:447–53.
pubmed: 9384461
pmcid: 2042877
doi: 10.1046/j.1365-2125.1997.t01-1-00606.x
Bhugra D, Bhui K. Ethnic and cultural factors in psychopharmacology. Adv Psychiatr Treat. 1999;5:89–95.
doi: 10.1192/apt.5.2.89
Lin KM, Finder E. Neuroleptic dosage for Asians. Am J Psychiatry. 1983;140:490–1.
pubmed: 6132560
doi: 10.1176/ajp.140.4.490
Farooq S. Ethnicity and clozapine metabolism. Br J Psychiatry. 1998;173:87–87.
pubmed: 9850214
doi: 10.1192/bjp.173.1.87a
Matsuda KT, Cho MC, Lin KM, Smith MW, Young AS, Adams JA. Clozapine dosage, serum levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients. Psychopharmacol Bull. 1996;32:253–7.
pubmed: 8783895
Tan MSA, Honarparvar F, Falconer JR, Parekh HS, Pandey P, Siskind DJ. A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions. Psychopharmacology. 2021;238:615–37.
pubmed: 33410989
doi: 10.1007/s00213-020-05746-y
Skokou M, Karavia EA, Drakou Z, Konstantinopoulou V, Kavakioti C-A, Gourzis P, et al. Adverse drug reactions in relation to clozapine plasma levels: a systematic review. Pharmaceuticals (Basel). 2022;15:817.
pubmed: 35890117
doi: 10.3390/ph15070817
Siskind D, Sharma M, Pawar M, Pearson E, Wagner E, Warren N, et al. Clozapine levels as a predictor for therapeutic response: a systematic review and meta-analysis. Acta Psychiatr Scand. 2021;144:422–32.
pubmed: 34374073
doi: 10.1111/acps.13361